The Board of Directors of Glenmark Pharmaceuticals Limited considered and approved audited financial results and recommended dividend.
GLENMARK · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Glenmark Pharmaceuticals reported mixed FY2026 results. On a consolidated basis, revenue grew 27% to ₹169.8 billion with PAT rising 30% to ₹13.6 billion and EPS at ₹48.26. However, standalone performance showed a loss of ₹2 billion versus profit of ₹16.1 billion in FY2025, impacted by exceptional items totaling ₹18 billion including antitrust litigation settlements (₹5 billion), inventory provisions (₹5.9 billion), and impairment charges (₹2.3 billion). The Board recommended a dividend of ₹2.5 per share (250%) for FY2026. The auditors issued an unmodified (clean) opinion on both standalone and consolidated financials.
The consolidated results show strong growth but the massive exceptional charge and standalone loss may create near-term volatility. The dividend offers shareholder compensation. Positive audit opinion removes going concern fears. The legal settlements remove litigation overhang but impacted profitability significantly.